The discovery of functional mutations in PCSK9, which cause familial hypercholesterolemia, and the crystal structure of PCSK9 have identified it as a distinct therapeutic target for cardiovascular disease [6, 7]. This evidence concerns the gene PCSK9 and cardiovascular disorder.